161 related articles for article (PubMed ID: 9149198)
1. Impaired fibrinolysis and increased protease levels in gastric and duodenal mucosa of patients with active duodenal ulcer.
Herszènyi L; Plebani M; Carraro P; De Paoli M; Cardin R; Di Mario F; Kusstatscher S; Naccarato R; Farinati F
Am J Gastroenterol; 1997 May; 92(5):843-7. PubMed ID: 9149198
[TBL] [Abstract][Full Text] [Related]
2. Reduced tissue type plasminogen activator activity of the gastroduodenal mucosa in peptic ulcer disease.
Wodziński MA; Bardhan KD; Reilly JT; Cooper P; Preston FE
Gut; 1993 Oct; 34(10):1310-4. PubMed ID: 8244093
[TBL] [Abstract][Full Text] [Related]
3. Histamine and tissue fibrinolytic activity in duodenal ulcer disease.
Ben-Hamida A; Adesanya AA; Man WK; Spencer J
Dig Dis Sci; 1998 Jan; 43(1):126-32. PubMed ID: 9508513
[TBL] [Abstract][Full Text] [Related]
4. Increased levels of cathepsin B and L, urokinase-type plasminogen activator and its inhibitor type-1 as an early event in gastric carcinogenesis.
Farinati F; Herszényi L; Plebani M; Carraro P; De Paoli M; Cardin R; Roveroni G; Rugge M; Nitti D; Grigioni WF; D'Errico A; Naccarato R
Carcinogenesis; 1996 Dec; 17(12):2581-7. PubMed ID: 9006092
[TBL] [Abstract][Full Text] [Related]
5. The role of cysteine and serine proteases in colorectal carcinoma.
Herszènyi L; Plebani M; Carraro P; De Paoli M; Roveroni G; Cardin R; Tulassay Z; Naccarato R; Farinati F
Cancer; 1999 Oct; 86(7):1135-42. PubMed ID: 10506696
[TBL] [Abstract][Full Text] [Related]
6. Cysteine and serine proteases in gastric cancer.
Plebani M; Herszènyi L; Cardin R; Roveroni G; Carraro P; Paoli MD; Rugge M; Grigioni WF; Nitti D; Naccarato R
Cancer; 1995 Aug; 76(3):367-75. PubMed ID: 8625115
[TBL] [Abstract][Full Text] [Related]
7. The relationship between mucosal histamine and fibrinolytic activity in duodenal ulcer disease.
Ben-Hamida A; Man WK; Spencer J
Inflamm Res; 1998; 47 Suppl 1():S56-7. PubMed ID: 9561415
[No Abstract] [Full Text] [Related]
8. Proteases as prognostic markers in cancer.
Duffy MJ
Clin Cancer Res; 1996 Apr; 2(4):613-8. PubMed ID: 9816210
[TBL] [Abstract][Full Text] [Related]
9. Immunocytochemical localization of cathepsins B, H, and L in the rat gastro-duodenal mucosa.
Furuhashi M; Nakahara A; Fukutomi H; Kominami E; Grube D; Uchiyama Y
Histochemistry; 1991; 95(3):231-9. PubMed ID: 2050543
[TBL] [Abstract][Full Text] [Related]
10. Comparison of potential biological markers cathepsin B, cathepsin L, stefin A and stefin B with urokinase and plasminogen activator inhibitor-1 and clinicopathological data of breast carcinoma patients.
Levicar N; Kos J; Blejec A; Golouh R; Vrhovec I; Frkovic-Grazio S; Lah TT
Cancer Detect Prev; 2002; 26(1):42-9. PubMed ID: 12088202
[TBL] [Abstract][Full Text] [Related]
11. Gastric mucosal plasminogen activators in Helicobacter pylori infection.
Götz JM; Vergouwe Y; Verspaget HW; Biemond I; Sier CF; Lamers CB; Veenendaal RA
Dig Dis Sci; 1996 Aug; 41(8):1577-82. PubMed ID: 8769282
[TBL] [Abstract][Full Text] [Related]
12. [Protease activities in gastric and colon cancer tissues].
Chung SM; Kawai K; Chung HM; Kawamoto K; Tada M
Nihon Shokakibyo Gakkai Zasshi; 1990 Aug; 87(8):1678-85. PubMed ID: 2232301
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of cathepsin B and urokinase plasminogen activator is associated with increased risk of recurrence and metastasis in patients with chondrosarcoma.
Häckel CG; Krueger S; Grote HJ; Oshiro Y; Hodges S; Johnston DA; Johnson ME; Roessner A; Ayala AG; Czerniak B
Cancer; 2000 Sep; 89(5):995-1003. PubMed ID: 10964329
[TBL] [Abstract][Full Text] [Related]
14. Expressions of urokinase-type plasminogen activator, its receptor and plasminogen activator inhibitor-1 in gastric cancer cells and effects of Helicobacter pylori.
Iwamoto J; Mizokami Y; Takahashi K; Nakajima K; Ohtsubo T; Miura S; Narasaka T; Takeyama H; Omata T; Shimokobe K; Ito M; Takehara H; Matsuoka T
Scand J Gastroenterol; 2005 Jul; 40(7):783-93. PubMed ID: 16109653
[TBL] [Abstract][Full Text] [Related]
15. Prognostic impact of proteolytic factors (urokinase-type plasminogen activator, plasminogen activator inhibitor 1, and cathepsins B, D, and L) in primary breast cancer reflects effects of adjuvant systemic therapy.
Harbeck N; Alt U; Berger U; Krüger A; Thomssen C; Jänicke F; Höfler H; Kates RE; Schmitt M
Clin Cancer Res; 2001 Sep; 7(9):2757-64. PubMed ID: 11555589
[TBL] [Abstract][Full Text] [Related]
16. Effective activation of the proenzyme form of the urokinase-type plasminogen activator (pro-uPA) by the cysteine protease cathepsin L.
Goretzki L; Schmitt M; Mann K; Calvete J; Chucholowski N; Kramer M; Günzler WA; Jänicke F; Graeff H
FEBS Lett; 1992 Feb; 297(1-2):112-8. PubMed ID: 1551416
[TBL] [Abstract][Full Text] [Related]
17. Cathepsins B and L in synovial fluids from patients with rheumatoid arthritis and the effect of cathepsin B on the activation of pro-urokinase.
Ikeda Y; Ikata T; Mishiro T; Nakano S; Ikebe M; Yasuoka S
J Med Invest; 2000 Feb; 47(1-2):61-75. PubMed ID: 10740981
[TBL] [Abstract][Full Text] [Related]
18. Effects of omeprazole and eradication of Helicobacter pylori on gastric and duodenal mucosal enzyme activities and DNA in duodenal ulcer patients.
Vetvik K; Schrumpf E; Mowinckel P; Aase S; Andersen KJ
Scand J Gastroenterol; 1994 Nov; 29(11):995-1000. PubMed ID: 7871380
[TBL] [Abstract][Full Text] [Related]
19. Link between Helicobacter pylori-associated gastritis and duodenal ulcer.
Saita H; Murakami M; Yoo JK; Teramura S; Dekigai H; Takahashi Y; Kita T
Dig Dis Sci; 1993 Jan; 38(1):117-22. PubMed ID: 8420742
[TBL] [Abstract][Full Text] [Related]
20. The role of urokinase-type plasminogen activator and its inhibitor PAI-1 in gastric cancer.
Herszényi L; Plebani M; Cardin R; Carraro P; De Paoli M; Roveroni G; Naccarato R; Farinati F
Acta Physiol Hung; 1995; 83(3):213-21. PubMed ID: 8852646
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
